Iza Denis
Overview
Explore the profile of Iza Denis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
192
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Paltoglou S, Das R, Townley S, Hickey T, Tarulli G, Coutinho I, et al.
Cancer Res
. 2017 May;
77(13):3417-3430.
PMID: 28473532
Alteration to the expression and activity of androgen receptor (AR) coregulators in prostate cancer is an important mechanism driving disease progression and therapy resistance. Using a novel proteomic technique, we...
2.
Das R, Gregory P, Fernandes R, Denis I, Wang Q, Townley S, et al.
Cancer Res
. 2016 Dec;
77(4):1021-1034.
PMID: 28011622
Serum levels of miR-194 have been reported to predict prostate cancer recurrence after surgery, but its functional contributions to this disease have not been studied. Herein, it is demonstrated that...
3.
El Bahhaj F, Denis I, Pichavant L, Delatouche R, Collette F, Linot C, et al.
Theranostics
. 2016 May;
6(6):795-807.
PMID: 27162550
Fast clearance, metabolism and systemic toxicity are major limits for the clinical use of anti-cancer drugs. Histone deacetylase inhibitors (HDACi) present these defects despite displaying promising anti-tumor properties on tumor...
4.
Denis I, El Bahhaj F, Collette F, Delatouche R, Gueugnon F, Pouliquen D, et al.
Eur J Med Chem
. 2015 Apr;
95:369-76.
PMID: 25827403
We report the synthesis of acid-responsive polymeric nanoparticles (NPs) consisting of a polymer-histone deacetylase inhibitor conjugate. An innovative aspect of this drug delivery particle lies in the NP conjugation of...
5.
Zwick V, Chatzivasileiou A, Deschamps N, Roussaki M, Simoes-Pires C, Nurisso A, et al.
Bioorg Med Chem Lett
. 2014 Dec;
24(23):5497-501.
PMID: 25455492
In this study, a total of 22 flavonoids were tested for their HDAC inhibitory activity using fluorimetric and BRET-based assays. Four aurones were found to be active in both assays...
6.
Denis I, Cellerin L, Gregoire M, Blanquart C
Oncotarget
. 2014 Nov;
5(22):11641-52.
PMID: 25361002
Malignant pleural mesothelioma (MPM) is a very aggressive form of cancer with a poor diagnosis and prognosis. The first line treatment for MPM is a combination of cisplatin and Pemetrexed,...
7.
Denis I, El Bahhaj F, Collette F, Delatouche R, Gueugnon F, Pouliquen D, et al.
Biomacromolecules
. 2014 Oct;
15(12):4534-43.
PMID: 25333409
In vivo histone deacetylase (HDAC) inhibition by vorinostat under clinically acceptable dosing is limited by its poor pharmacokinetics properties. A new type of nontoxic pH-responsive delivery system has been synthesized...
8.
Gueugnon F, Denis I, Pouliquen D, Collette F, Delatouche R, Heroguez V, et al.
Biomacromolecules
. 2013 Jun;
14(7):2396-402.
PMID: 23731363
We described a norbornenyl-poly(ethylene oxide) nanoparticles ligand-free generic platform, made fluorescent with straightforward preparation by ring-opening metathesis polymerization (ROMP). Our method allowed to easily obtain a drug delivery system (DDS)...
9.
Delatouche R, Denis I, Grinda M, El Bahhaj F, Baucher E, Collette F, et al.
Eur J Pharm Biopharm
. 2013 Mar;
85(3 Pt B):862-72.
PMID: 23537575
The aim of this study was to develop clickable prodrugs bearing a tunable pH responsive linker designed for acidic pH-mediated release of histone deacetylase inhibitors. HDACi are an important class...